EDAP to Present At Cowen and Company 28th Annual Healthcare Conference

Planet edap Inc.
Mar 10,2008

EDAP to Present At Cowen and Company 28th Annual Healthcare Conference

EDAP to Present At Cowen and Company 28th Annual Healthcare Conference

LYON, France, March 10, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer, announced today that Marc Oczachowski, Chief Executive Officer, and Eric Soyer, Chief Financial Officer, are scheduled to present at the Cowen and Company 28th Annual Healthcare Conference at the Marriott Copley Place in Boston, MA on Tuesday, March 18, 2008 at 3:10 p.m. ET.

Management will provide a general corporate update and review of several important milestones, including the expansion of Ablatherm-HIFU technology throughout Europe and a U.S. clinical trial update.

A live Web cast of the presentation will be available on EDAP's Web site at www.edap-tms.com.

A replay of the Web cast will be available for 30 days after the date of the presentation.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com and http://www.hifu-planet.com or http:/www./urotoday.com/HIFU.

CONTACT: EDAP TMS SA
         Blandine Confort, Investor Relations/Legal Affairs
         +33 4 72 15 31 72
         bconfort@edap-tms.com
         
         The Ruth Group
         Investors:
         Stephanie Carrington
         646-536-7017 
         scarrington@theruthgroup.com

         R.J. Pellegrino
         646-536-7009
         rpellegrino@theruthgroup.com